Zymeworks (ZYME) EBT (2021 - 2026)

Zymeworks has disclosed EBT across 6 years of filings, most recently posting -$46.4 million for Q1 2026.

• EBT for Q1 2026 came in at -$46.4 million, down 109.36% year-over-year; the trailing twelve-month figure through Mar 2026 was -$104.0 million (up 2.99% YoY), and the FY2025 annual result was -$79.8 million, up 31.61% from the prior year.
• EBT came in at -$46.4 million for Q1 2026 at Zymeworks, down from -$41.5 million in the prior quarter.
• In the past five years, EBT ranged from a high of $320.4 million in Q4 2022 to a low of -$72.7 million in Q1 2022.
• The 5-year median for EBT is -$29.6 million (2024), against an average of -$13.3 million.
• Across the five-year window, EBT jumped 890.75% in 2022 and tumbled 133.15% in 2025, its largest moves.
• Zymeworks' EBT stood at $320.4 million in 2022, then plunged by 105.99% to -$19.2 million in 2023, then rose by 7.36% to -$17.8 million in 2024, then sank by 133.15% to -$41.5 million in 2025, then decreased by 11.75% to -$46.4 million in 2026.
• The last three EBT figures came in at -$46.4 million (Q1 2026), -$41.5 million (Q4 2025), and -$18.3 million (Q3 2025), per Business Quant data.